1 Supplemental Information : Restoring consciousness with vagus nerve stimulation

M. Corazzol,Guillaume Lio,A. Lefevre,G. Deiana,L. Tell,N. André-Obadia,P. Bourdillon,M. Guenot,M. Desmurget,J. Luauté,A. Sirigu

Abstract:

What problem does this paper attempt to address?

Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. II. Porphyrins reacting with the V3 loop of gp120*

Alexander Robert Neurath,Nathan Strick,P. Haberfield,Shibo Jiang

DOI: https://doi.org/10.1177/095632029200300108

1992-01-01

Abstract:Recent observations that haemin inhibited the replication of the human immunodeficiency virus (HIV-1) and the reaction between the HIV-1 envelope glycoprotein gp120 and antibodies specific for the V3 hypervariable loop of this glycoprotein were an enticement to determine whether or not additional porphyrins had similar activities. Several porphyrin derivatives, particularly meso-tetra (4-carboxyphenyl) porphine, were more potent inhibitors of HIV-1 replication than haemin. They blocked the binding of homologous antibodies to synthetic peptides corresponding to V3 hypervariable loops of 21 distinct HIV-1 isolates, and inhibited the replication in lymphocytic (MT-2) and promonocytic (U937) cell lines of several HIV-1 isolates, tested (IIIB, RF, SF-2, and MN). Compounds with inhibitory activity had a tetrapyrrole ring and, carboxyl or sulphonate groups. However, antiviral activity depended on minor structural differences between distinct derivatives endowed with these two features. Metalloporphyrins had a drastically reduced antiviral activity in comparison with the corresponding porphyrins. An understanding of the relationship between the structure of porphyrins and their antiviral effects perceptible from the results presented, is expected to lead to the design of additional derivatives with more potent antiviral activity and to unravelling of molecular details involved in the association between the V3 loop of gp120 and antiviral compounds targeted to this loop.
A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro

Yao Cheng,Lun K Tsou,Jianfeng Cai,Toshihiro Aya,Ginger E Dutschman,Elizabeth A Gullen,Susan P Grill,Annie Pei-Chun Chen,Brett D Lindenbach,Andrew D Hamilton,Yung-Chi Cheng

DOI: https://doi.org/10.1128/AAC.01206-09

Abstract:Recent years have seen the rapid advancement of new therapeutic agents against hepatitis C virus (HCV) in response to the need for treatment that is unmet by interferon (IFN)-based therapies. Most antiviral drugs discovered to date are small molecules that modulate viral enzyme activities. In the search for highly selective protein-binding molecules capable of disrupting the viral life cycle, we have identified a class of anionic tetraphenylporphyrins as potent and specific inhibitors of the HCV replicons. Based on the structure-activity relationship studies reported herein, meso-tetrakis-(3,5-dicarboxy-4,4'-biphenyl) porphyrin was found to be the most potent inhibitor of HCV genotype 1b (Con1) replicon systems but was less effective against the genotype 2a (JFH-1) replicon. This compound induced a reduction of viral RNA and protein levels when acting in the low nanomolar range. Moreover, the compound could suppress replicon rebound in drug-treated cells and exhibited additive to synergistic effects when combined with protease inhibitor BILN 2061 or with IFN-alpha-2a. Our results demonstrate the potential use of tetracarboxyphenylporphyrins as potent anti-HCV agents.
Metal binding 6-arylthio-3-hydroxypyrimidine-2,4-diones inhibited human cytomegalovirus by targeting the pUL89 endonuclease of the terminase complex

Lei Wang,Tiffany C Edwards,Rajkumar Lalji Sahani,Jiashu Xie,Hideki Aihara,Robert J Geraghty,Zhengqiang Wang

DOI: https://doi.org/10.1016/j.ejmech.2021.113640

2021-10-15

Abstract:The genome packaging of human cytomegalovirus (HCMV) requires a divalent metal-dependent endonuclease activity localized to the C-terminus of pUL89 (pUL89-C), which is reminiscent of RNase H-like enzymes in active site structure and catalytic mechanism. Our previous work has shown that metal-binding small molecules can effectively inhibit pUL89-C while conferring significant antiviral activities. In this report we generated a collection of 43 metal-binding small molecules by repurposing analogs of the 6-arylthio-3-hydroxypyrimidine-2,4-dione chemotype previously synthesized for targeting HIV-1 RNase H, and by chemically synthesizing new N-1 analogs. The analogs were subjected to two parallel screening assays: the pUL89-C biochemical assay and the HCMV antiviral assay. Compounds with significant inhibition from each assay were further tested in a dose-response fashion. Single dose cell viability and PAMPA cell permeability were also conducted and considered in selecting compounds for the dose-response antiviral testing. These assays identified a few analogs displaying low μM inhibition against pUL89-C in the biochemical assay and HCMV replication in the antiviral assay. The target engagement was further evaluated via a thermal shift assay using recombinant pUL89-C and molecular docking. Overall, our current work identified novel inhibitors of pUL89-C with significant antiviral activities and further supports targeting pUL89-C with metal-binding small molecules as an antiviral approach against HCMV.
Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Desaboini Nageswara Rao,Jacqueto Zephyr,Mina Henes,Elise T. Chan,Ashley N. Matthew,Adam K. Hedger,Hasahn L. Conway,Mohsan Saeed,Alicia Newton,Christos J. Petropoulos,Wei Huang,Nese Kurt Yilmaz,Celia A. Schiffer,Akbar Ali

DOI: https://doi.org/10.1021/acs.jmedchem.1c00554

IF: 8.039

2021-08-18

Journal of Medicinal Chemistry

Abstract:The three pan-genotypic HCV NS3/4A protease inhibitors (PIs) currently in clinical use—grazoprevir, glecaprevir, and voxilaprevir—are quinoxaline-based P2–P4 macrocycles and thus exhibit similar resistance profiles. Using our quinoxaline-based P1–P3 macrocyclic lead compounds as an alternative chemical scaffold, we explored structure–activity relationships (SARs) at the P2 and P4 positions to develop pan-genotypic PIs that avoid drug resistance. A structure-guided strategy was used to design and synthesize two series of compounds with different P2 quinoxalines in combination with diverse P4 groups of varying sizes and shapes, with and without fluorine substitutions. Our SAR data and cocrystal structures revealed the interplay between the P2 and P4 groups, which influenced inhibitor binding and the overall resistance profile. Optimizing inhibitor interactions in the S4 pocket led to PIs with excellent antiviral activity against clinically relevant PI-resistant HCV variants and genotype 3, providing potential pan-genotypic inhibitors with improved resistance profiles.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00554.Synthesis details and characterization data for intermediates 55–67, protease inhibitors 4–27 and 28–51, and carbonate intermediates 69a–x; X-ray data collection and refinement statistics (PDF)Molecular formula strings (CSV)This article has not yet been cited by other publications.

chemistry, medicinal
Allosteric inhibitors of the NS3 protease from the hepatitis C virus

Olga Abian,Sonia Vega,Javier Sancho,Adrian Velazquez-Campoy

DOI: https://doi.org/10.1371/journal.pone.0069773

IF: 3.7

2013-07-30

PLoS ONE

Abstract:The nonstructural protein 3 (NS3) from the hepatitis C virus processes the non-structural region of the viral precursor polyprotein in infected hepatic cells. The NS3 protease activity has been considered a target for drug development since its identification two decades ago. Although specific inhibitors have been approved for clinical therapy very recently, resistance-associated mutations have already been reported for those drugs, compromising their long-term efficacy. Therefore, there is an urgent need for new anti-HCV agents with low susceptibility to resistance-associated mutations. Regarding NS3 protease, two strategies have been followed: competitive inhibitors blocking the active site and allosteric inhibitors blocking the binding of the accessory viral protein NS4A. In this work we exploit the intrinsic Zn(+2)-regulated plasticity of the protease to identify a new type of allosteric inhibitors. In the absence of Zn(+2), the NS3 protease adopts a partially-folded inactive conformation. We found ligands binding to the Zn(+2)-free NS3 protease, trap the inactive protein, and block the viral life cycle. The efficacy of these compounds has been confirmed in replicon cell assays. Importantly, direct calorimetric assays reveal a low impact of known resistance-associated mutations, and enzymatic assays provide a direct evidence of their inhibitory activity. They constitute new low molecular-weight scaffolds for further optimization and provide several advantages: 1) new inhibition mechanism simultaneously blocking substrate and cofactor interactions in a non-competitive fashion, appropriate for combination therapy; 2) low impact of known resistance-associated mutations; 3) inhibition of NS4A binding, thus blocking its several effects on NS3 protease.
Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation

Yali Zhou,Yan Zhao,Yaoying Gao,Wenjun Hu,Yan Qu,Ning Lou,Ying Zhu,Xiaoping Zhang,Hongmei Yang

DOI: https://doi.org/10.1186/s13046-017-0510-8

2017-03-10

Abstract:BackgroundGrowing evidence suggests that hepatitis C virus (HCV) contributes to hepatocellular carcinoma (HCC) by directly modulating oncogenic signaling pathways. Protein phosphatase magnesium-dependent 1A (PPM1A) has recently emerged as an important tumor suppressor as it can block a range of tumor-centric signaling pathways through protein dephosphorylation. However, the role and regulatory mechanisms of PPM1A in HCV-infected cells have not been reported.MethodsTotal, cytoplasmic, and nuclear PPM1A protein after HCV infection or overexpression of HCV nonstructural protein 3 (NS3) were detected by western blotting. The expression of PPM1A in normal liver and HCV-related HCC tissues was quantified by immunohistochemistry. The effects of HCV infection and NS3 expression on the PPM1A protein level were systematically analyzed, and the ubiquitination level of PPM1A was determined by precipitation with anti-PPM1A and immunoblotting with either anti-ubiquitin or anti-PPM1A antibody. Finally, the roles of NS3 and PPM1A in hepatoma cell migration and invasion were assessed by wound healing and transwell assays, respectively.ResultsHCV infection and replication decreased PPM1A abundance, mediated by NS3, in hepatoma cells. Compared to normal liver tissues, the expression of PPM1A was significantly decreased in the HCC tumor tissues and adjacent non-tumor tissues. NS3 directly interacted with PPM1A to promote PPM1A ubiquitination and degradation, which was dependent on its protease domain. Blockade of PPM1A through small interfering RNA significantly promoted HCC cell migration, invasion, and epithelial mesenchymal transition (EMT), which were further intensified by TGF-β1 stimulation, in vitro. Furthermore, restoration of PPM1A abrogated the NS3-mediated promotion of HCC migration and invasion to a great extent, which was dependent on its protein phosphatase function.ConclusionsOur findings demonstrate that the HCV protein NS3 can downregulate PPM1A by promoting its ubiquitination and proteasomal degradation, which might contribute to the migration and invasion of hepatoma cells and may represent a new strategy of HCV in carcinogenesis.

oncology
PK/PD investigation of antiviral host matriptase/TMPRSS2 inhibitors in cell models

Dávid Gamba,Nicholas van Eijk,Katalin Lányi,Katalin Monostory,Torsten Steinmetzer,András Marosi,Anita Rácz,Dávid Bajusz,Diana Kruhl,Eva Böttcher-Friebertshäuser,Erzsébet Pászti-Gere

DOI: https://doi.org/10.1038/s41598-024-67633-2

IF: 4.6

2024-07-20

Scientific Reports

Abstract:Certain corona- and influenza viruses utilize type II transmembrane serine proteases for cell entry, making these enzymes potential drug targets for the treatment of viral respiratory infections. In this study, the cytotoxicity and inhibitory effects of seven matriptase/TMPRSS2 inhibitors (MI-21, MI-463, MI-472, MI-485, MI-1900, MI-1903, and MI-1904) on cytochrome P450 enzymes were evaluated using fluorometric assays. Additionally, their antiviral activity against influenza A virus subtypes H1N1 and H9N2 was assessed. The metabolic depletion rates of these inhibitors in human primary hepatocytes were determined over a 120-min period by LC–MS/MS, and PK parameters were calculated. The tested compounds, with the exception of MI-21, displayed potent inhibition of CYP3A4, while all compounds lacked inhibitory effects on CYP1A2, CYP2C9, CYP2C19, and CYP2D6. The differences between the CYP3A4 activity within the series were rationalized by ligand docking. Elucidation of PK parameters showed that inhibitors MI-463, MI-472, MI-485, MI-1900 and MI-1904 were more stable compounds than MI-21 and MI-1903. Anti-H1N1 properties of inhibitors MI-463 and MI-1900 and anti-H9N2 effects of MI-463 were shown at 20 and 50 μM after 24 h incubation with the inhibitors, suggesting that these inhibitors can be applied to block entry of these viruses by suppressing host matriptase/TMPRSS2-mediated cleavage.

multidisciplinary sciences
Discovery of Novel 3-Hydroxyquinazoline-2,4(1h,3h)-dione Derivatives: A Series of Metal Ion Chelators with Potent Anti-HCV Activities.

Yang Cao,Abudumijiti Aimaiti,Zeyun Zhu,Lu Zhou,Deyong Ye

DOI: https://doi.org/10.3390/ijms23115930

IF: 5.6

2022-01-01

International Journal of Molecular Sciences

Abstract:Millions of people worldwide suffer from acute or chronic liver inflammation caused by the hepatitis C virus (HCV). Metal ion chelators have achieved widespread success in the development of antiviral drugs. Some inhibitors with metal ion chelating structures have been proven to have good inhibitory activities on non-structural protein 5B (NS5B) polymerase. However, most of the reported metal ion chelators showed poor anti-HCV potency at the cellular level. Hence, we designed and synthesized a series of 3-hydroxyquinazoline-2,4(1H,3H)-dione derivatives with novel metal ion chelating structures. Typical compounds such as 21h, 21k, and 21t showed better anti-HCV activities than ribavirin with EC50 values less than 10 μM. 21t is currently known as one of the metal ion chelators with the best anti-HCV potency (EC50 = 2.0 μM) at the cellular level and has a better therapeutic index (TI > 25) as compared to ribavirin and the reported compound 6. In the thermal shift assay, the representative compounds 21e and 21k increased the melting temperature (Tm) of NS5B protein solution by 1.6 °C and 2.1 °C, respectively, at the test concentration, indicating that these compounds may exert an anti-HCV effect by targeting NS5B. This speculation was also supported by our molecular docking studies and ultraviolet-visible (UV-Vis) spectrophotometry assay, in which the possibility of binding of 3-hydroxyquinazoline-2,4(1H,3H)-diones with Mg2+ in the NS5B catalytic center was observed.
Virucidal activity of porphyrin-based metal-organic frameworks against highly pathogenic coronaviruses and hepatitis C virus

Orfeas-Evangelos Plastiras,Peggy Bouquet,Imelda Raczkiewicz,Sandrine Belouzard,Esther Martin De Fourchambault,Jeremy Dhainaut,Jean-Philippe Dacquin,Anne Goffard,Christophe Volkringer

DOI: https://doi.org/10.1016/j.mtbio.2024.101165

2024-08-02

Abstract:The antiviral effect of four porphyrin-based Metal-Organic Frameworks (PMOFs) with Al and Zr, namely Al-TCPP, PCN-222, PCN-223 and PCN-224 was assessed for the first time against HCoV-229E, two highly pathogenic coronaviruses (SARS-CoV-2 and MERS-CoV) and hepatitis C virus (HCV). Infection tests in vitro were done under dark or light exposure for different contact times, and it was found that 15 min of light exposure were enough to give antiviral properties to the materials, therefore inactivating HCoV-229E by 99.98 % and 99.96 % for Al-TCPP and PCN-222. Al-TCPP diminished the viral titer of SARS-CoV-2 greater than PCN-222 in the same duration of light exposure, having an effect of 99.95 % and 93.48 % respectively. Next, Al-TCPP was chosen as the best candidate possessing antiviral properties and was tested against MERS-CoV and HCV, showcasing a reduction of infectivity of 99.28 % and 98.15 % respectively for each virus. The mechanism of the antiviral activity of the four PMOFs was found to be the production of singlet oxygen 1O2 from the porphyrin ligand TCPP when exposed to visible light, by using sodium azide (NaN3) as a scavenger, that can later attack the phospholipids on the envelope of the viruses, thus preventing their entry into the cells.
Heme and HO-1 Inhibition of HCV, HBV, and HIV

Warren N. Schmidt,M. Meleah Mathahs,Zhaowen Zhu

DOI: https://doi.org/10.3389/fphar.2012.00129

IF: 5.6

2012-01-01

Frontiers in Pharmacology

Abstract:Hepatitis C virus, human immunodeficiency virus, and hepatitis B virus are chronic viral infections that cause considerable morbidity and mortality throughout the world. In the decades following the identification and sequencing of these viruses, in vitro experiments demonstrated that heme oxygenase-1, its oxidative products, and related compounds of the heme oxygenase system inhibit replication of all 3 viruses. The purpose of this review is to critically evaluate and summarize the seminal studies that described and characterized this remarkable behavior. It will also discuss more recent work that discovered the antiviral mechanisms and target sites of these unique antiviral agents. In spite of the fact that these viruses are diverse pathogens with quite profound differences in structure and life cycle, it is significant that heme and related compounds show striking similarity for viral target sites across all three species. Collectively, these findings strongly indicate that we should move forward and develop heme and related tetrapyrroles into versatile antiviral agents that could be used therapeutically in patients with single or multiple viral infections.

pharmacology & pharmacy
Phosphoramidate Protides of 2 '-C-methylguanosine As Highly Potent Inhibitors of Hepatitis C Virus. Study of Their in Vitro and in Vivo Properties

Christopher McGuigan,Arnaud Gilles,Karolina Madela,Mohamed Aljarah,Sabrina Holl,Sarah Jones,John Vernachio,Jeff Hutchins,Brenda Ames,K. Dawn Bryant,Elena Gorovits,Babita Ganguly,Damound Hunley,Andrea Hall,Alexander Kolykhalov,Yule Liu,Jerry Muhammad,Nicholas Raja,Robin Walters,Jin Wang,Stanley Chamberlain,Geoffrey Henson

DOI: https://doi.org/10.1021/jm1003792

IF: 8.039

2010-01-01

Journal of Medicinal Chemistry

Abstract:Hepatitis C virus infection constitutes a serious health problem in need of more effective therapies. Nucleoside analogues with improved exposure, efficacy, and selectivity are recognized as likely key components of future HCV therapy. 2'-C-Methylguanosine triphosphate has been known as a potent inhibitor of HCV RNA polymerase for some time, but the parent nucleoside is only moderately active due to poor intracellular phosphorylation. We herein report the application of phosphoramidate ProTide technology to bypass the rate-limiting initial phosphorylation of this nucleoside. Over 30 novel ProTides are reported, with variations in the aryl, ester, and amino acid regions. L-Alanine compounds are recognized as potent and selective inhibitors of HCV in replicon assay but lack rodent plasma stability despite considerable ester variation. Amino acid variation retaining the lead benzyl ester moiety gives an increase in rodent stability but at the cost of potency. Finally L-valine esters with ester variation lead to potent, stable compounds. Pharmacokinetic studies on these agents in the mouse reveal liver exposure to the bioactive triphosphate species following single oral dosing. Systemic exposure of the ProTide and parent nucleoside are low, indicating possible low toxicity in vivo, while liver concentrations of the active species may be predictive of efficacy in the clinic. This represents one of the most thorough cross-species studies of ProTides to date.
Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)

Na Yang,Chaomin Sun,Lixin Zhang,Jianguo Liu,Fuhang Song

DOI: https://doi.org/10.3389/fmicb.2017.02153

IF: 5.2

2017-11-02

Frontiers in Microbiology

Abstract:Hepatitis C virus (HCV) leads to severe liver diseases, including liver fibrosis, cirrhosis and hepatocellular carcinoma. Non-structural protein 3 helicase (NS3h) and non-structural protein 5B RNA-dependent RNA polymerase (NS5B) are involved in the replication of HCV RNA genome, and have been proved to be excellent targets for discovery of direct-acting antivirals. In this study, two high-throughput screening systems, fluorescence polarization (FP)-based ssDNA binding assay and fluorescence intensity (FI)-based dsRNA formation assay, were constructed to identify candidate NS3h and NS5B inhibitors, respectively. A library of approximately 800 small molecules and crude extracts, derived from marine microorganisms or purchased from the National Compound Resource Center, China, were screened, with three hits selected for further study. Natural compound No.3A5, isolated from marine fungi, inhibited NS3h activity with an IC50 value of 2.8 μM. We further demonstrated that compound No.3A5 inhibited the abilities of NS3h to bind ssDNA in electrophoretic mobility shift assay and to hydrolyze ATP. The NS3h-inhibitory activity of compound No.3A5 was reversible in our dilution assay, which indicated there was no stable NS3h-No.3A5 complex formed. Additionally, compound No.3A5 exhibited no binding selectivity on NS3h or single strand binding protein of Escherichia coli. In NS5B assays, commercial compounds No.39 and No.94 previously reported as kinase inhibitors were found to disrupt dsRNA formation, and their IC50 values were 62.9 and 18.8 μM, respectively. These results highlight how identifying new uses for existing drugs is an effective method for discovering novel HCV inhibitors. To our knowledge, all inhibitors reported in this study were originally discovered with HCV anti-non-structural protein activities in vitro.

microbiology
Discovery Of Metal Ions Chelator Quercetin Derivatives With Potent Anti-Hcv Activities

Dongwei Zhong,Mingming Liu,Yang Cao,Yelin Zhu,Shihui Bian,Jiayi Zhou,Fengjie Wu,Kum-Chol Ryu,Lu Zhou,Deyong Ye

DOI: https://doi.org/10.3390/molecules20046978

IF: 4.6

2015-01-01

Molecules

Abstract:Analogues or isosteres of ,-diketoacid (DKA) 1a show potent inhibition of hepatitis C virus (HCV) NS5B polymerase through chelation of the two magnesium ions at the active site. The anti-HCV activity of the flavonoid quercetin (2) could partly be attributed to it being a structural mimic of DKAs. In order to delineate the structural features required for the inhibitory effect and improve the anti-HCV potency, two novel types of quercetin analogues, 7-O-arylmethylquercetins and quercetin-3-O-benzoic acid esters, were designed, synthesized and evaluated for their anti-HCV properties in cell-based assays. Among the 38 newly synthesized compounds, 7-O-substituted derivative 3i and 3-O-substituted derivative 4f were found to be the most active in the corresponding series (EC50 = 3.8 M and 9.0 M, respectively). Docking studies suggested that the quercetin analogues are capable of establishing key coordination with the two magnesium ions as well as interactions with residues at the active site of HCV NS5B.
Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis

Weiwei Xue,Yihe Ban,Huanxiang Liu,Xiaojun Yao

DOI: https://doi.org/10.1021/ci400060j

IF: 6.162

2013-06-28

Journal of Chemical Information and Modeling

Abstract:Hepatitis C virus (HCV) NS3/4A protease is an important and attractive target for anti-HCV drug development and discovery. Vaniprevir (phase III clinical trials) and MK-5172 (phase II clinical trials) are two potent antiviral compounds that target NS3/4A protease. However, the emergence of resistance to these two inhibitors reduced the effectiveness of vaniprevir and MK-5172 against viral replication. Among the drug resistance mutations, three single-site mutations at residues Arg155, Ala156, and Asp168 in NS3/4A protease are especially important due to their resistance to nearly all inhibitors in clinical development. A detailed understanding of drug resistance mechanism to vaniprevir and MK-5172 is therefore very crucial for the design of novel potent agents targeting viral variants. In this work, molecular dynamics (MD) simulation, binding free energy calculation, free energy decomposition, residue interaction network (RIN), and substrate envelope analysis were used to study the detailed drug resistance mechanism of the three mutants R155K, A156T, and D168A to vaniprevir and MK-5172. MD simulation was used to investigate the binding mode for these two inhibitors to wild-type and resistant mutants of HCV NS3/4A protease. Binding free energy calculation and free energy decomposition analysis reveal that drug resistance mutations reduced the interactions between the active site residues and substituent in the P2 to P4 linker of vaniprevir and MK-5172. Furthermore, RIN and substrate envelope analysis indicate that the studied mutations of the residues are located outside the substrate (4B5A) binding site and selectively decrease the affinity of inhibitors but not the activity of the enzyme and consequently help NS3/4A protease escape from the effect of the inhibitors without influencing the affinity of substrate binding. These findings can provide useful information for understanding the drug resistance mechanism against vaniprevir and MK-5172. The results can also provide some potential clues for further design of novel inhibitors that are less susceptible to drug resistance.

chemistry, multidisciplinary, medicinal,computer science, interdisciplinary applications, information systems
Forum focus -- our residential care homes are losing expert nurses.

H. Heath

DOI: https://doi.org/10.7748/nop2013.11.25.9.10.s13

2013-11-01

Nursing Older People

Abstract:
Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors

Cheng Li,Latha Nair,Tongtong Liu,Fangbiao Li,John Pichardo,Sony Agrawal,Robert Chase,Xiao Tong,Annette S. Uss,Stephane Bogen,F. George Njoroge,Richard A. Morrison,K.-C. Cheng

DOI: https://doi.org/10.1016/j.bcp.2007.10.031

IF: 6.1

2008-03-01

Biochemical Pharmacology

Abstract:Parallel artificial membrane permeability assay (PAMPA) and Caco-2 cells have been frequently used for the evaluation of in vitro permeability of new chemical entities. In this study we evaluated the correlation between permeability, assessed by both methods, and the cellular potency of 34 novel hepatitis C virus (HCV) protease inhibitors. Two types of assays were used to determine the potency of HCV protease inhibitors: a cell-free assay that evaluates the intrinsic affinity (K(i)) between the protease and the inhibitor and a cell-based replicon assay that determines the inhibitors' IC90. When the K(i)/IC90 ratios were compared with the PAMPA permeability and the Caco-2 permeability by linear regression analysis, a reasonable correlation was found between the K(i)/IC90 ratio and PAMPA permeability (r2=0.76) but not with Caco-2 permeability (r2=0.29). Correlations were also assessed between K(i)/IC90 ratios and the following physico-chemical properties: logP (r2=0.41), logD (r2=0.58), clogP (r2=0.13), and mlogP (r2=0.30). These results suggest that passive permeability may play a role in the uptake and cellular activity of these HCV protease inhibitors, and that PAMPA was more predictive of cellular activity than physico-chemical properties or Caco-2 permeability.

pharmacology & pharmacy
Comparative study on heme-containing enzyme-like catalytic activities of water-soluble metalloporphyrins

Jian-Yu Liu,Xiao-Feng Li,Zhong-Xian Guo,Yuan-Zong Li,Ai-Jin Huang,Wen-Bao Chang

DOI: https://doi.org/10.1016/S1381-1169(01)00331-4

2002-01-01

Abstract:This paper reported the heme-containing enzyme-like catalytic activities of 15 water-soluble metalloporphyrins (M-Ps) produced from three metal ions (Fe, Mn and Co) and five porphophine ligands, i.e. porphyrin IX, meso-tetrakis(p-sulfonatophenyl)porphophine (TPPS4), meso-tetrakis(4-carboxy-phenyl)porphophine (TCPP), meso-tetrakis[4-(N-trimethyl)aminophenyl]porphophine (TTMAPP) and meso-tetrakis(4-N-methylpyridinium)porphophine (TMPyP). Their catalytic activities of catalase, peroxidase and cytochrome P-450 on the typical reactions were systematically studied and compared. The results indicated that the metalloporphyrins with Fe and Mn as central ions show high catalytic activities of catalase and peroxidase at pH range of 10.5–11.5, and among them Fe-TMPyP and Fe-TTMAPP have the highest catalytic capability, while all Co-porphyrins have weak activities. Interestingly, only Mn-TMPyP of the 15 metalloporphyrins shows relatively high cytochrome P-450-like activity. The presence of imidazole has enhancement effects to different extent on the peroxidase-like activities of these metalloporphyrins and negligible effects on catalase-like activities.
Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease

Kanzal Iman,Muhammad Usman Mirza,Fazila Sadia,Matheus Froeyen,John F Trant,Safee Ullah Chaudhary

DOI: https://doi.org/10.3390/v16081250

2024-08-03

Viruses

Abstract:The emergence of drug-resistance-inducing mutations in Hepatitis C virus (HCV) coupled with genotypic heterogeneity has made targeting NS3/4A serine protease difficult. In this work, we investigated the mutagenic variations in the binding pocket of Genotype 3 (G3) HCV NS3/4A and evaluated ligands for efficacious inhibition. We report mutations at 14 positions within the ligand-binding residues of HCV NS3/4A, including H57R and S139P within the catalytic triad. We then modelled each mutational variant for pharmacophore-based virtual screening (PBVS) followed by covalent docking towards identifying a potential covalent inhibitor, i.e., cpd-217. The binding stability of cpd-217 was then supported by molecular dynamic simulation followed by MM/GBSA binding free energy calculation. The free energy decomposition analysis indicated that the resistant mutants alter the HCV NS3/4A-ligand interaction, resulting in unbalanced energy distribution within the binding site, leading to drug resistance. Cpd-217 was identified as interacting with all NS3/4A G3 variants with significant covalent docking scores. In conclusion, cpd-217 emerges as a potential inhibitor of HCV NS3/4A G3 variants that warrants further in vitro and in vivo studies. This study provides a theoretical foundation for drug design and development targeting HCV G3 NS3/4A.
Interesting uses of beta blockers: 5 Beta blockers in thyrotoxicosis.

R. Larkins,P. Heyma

1981-10-01

Abstract:
Studies of Benzothiadiazine Derivatives As Hepatitis C Virus NS5B Polymerase Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics.

X. Wang,Wei Yang,Xiaojie Xu,H. Zhang,Y. Li,Y. Wang

DOI: https://doi.org/10.2174/092986710791859298

IF: 4.74

2010-01-01

Current Medicinal Chemistry

Abstract:In order to explore the structure-activity correlation of benzothiadiazine series as inhibitors of genotype 1a HCV polymerase, a set of ligand- and receptor-based 3D-QSAR models were, for the first time, developed in the present work employing Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Index Analysis (CoMSIA) for 239 promising molecules. In addition, homology modeling, docking analysis, and molecular dynamics simulation (MD) were also applied to elucidate the probable binding modes of these inhibitors at the allosteric site of the enzyme. The statistical model validations assure the reliability of the obtained QSAR models. Changes in the binding affinity of the inhibitors attributing to modifications in the aromatic rings could be rationalized by the steric, electrostatic, hydrophobic, and hydrogen bond acceptor properties. (i) Hydrophobic substituents with similar size of benzo group like isosteres are preferential at positions 1 and 2 (ring B of benzothiadiazines). (ii) Substituents at position-3 containing a linear alkyl chain (four or five carbon atoms) or a branched alkyl chain (five-eight carbons) can increase the inhibitory activity by one to two orders of magnitude. (iii) A polar substituent like methanesulfonamide group at position-14 can enhance the activity of the drug by providing a hydrogen bonding interaction with the protein target. The results obtained from this work provide important guidelines in design of novel benzothiadiazine analogs as inhibitors of HCV genotype 1a NS5B. Keywords: HCV NS5B, benzothiadiazine analogs, allosteric site, 3D-QSAR, CoMFA, CoMSIA, molecular docking, molecular dynamics

1 Supplemental Information : Restoring consciousness with vagus nerve stimulation

Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays. II. Porphyrins reacting with the V3 loop of gp120*

A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro

Metal binding 6-arylthio-3-hydroxypyrimidine-2,4-diones inhibited human cytomegalovirus by targeting the pUL89 endonuclease of the terminase complex

Discovery of Quinoxaline-Based P1–P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants

Allosteric inhibitors of the NS3 protease from the hepatitis C virus

Hepatitis C virus NS3 protein enhances hepatocellular carcinoma cell invasion by promoting PPM1A ubiquitination and degradation

PK/PD investigation of antiviral host matriptase/TMPRSS2 inhibitors in cell models

Discovery of Novel 3-Hydroxyquinazoline-2,4(1h,3h)-dione Derivatives: A Series of Metal Ion Chelators with Potent Anti-HCV Activities.

Virucidal activity of porphyrin-based metal-organic frameworks against highly pathogenic coronaviruses and hepatitis C virus

Heme and HO-1 Inhibition of HCV, HBV, and HIV

Phosphoramidate Protides of 2 '-C-methylguanosine As Highly Potent Inhibitors of Hepatitis C Virus. Study of Their in Vitro and in Vivo Properties

Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)

Discovery Of Metal Ions Chelator Quercetin Derivatives With Potent Anti-Hcv Activities

Computational Study on the Drug Resistance Mechanism against HCV NS3/4A Protease Inhibitors Vaniprevir and MK-5172 by the Combination Use of Molecular Dynamics Simulation, Residue Interaction Network, and Substrate Envelope Analysis

Forum focus -- our residential care homes are losing expert nurses.

Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors

Comparative study on heme-containing enzyme-like catalytic activities of water-soluble metalloporphyrins

Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease

Interesting uses of beta blockers: 5 Beta blockers in thyrotoxicosis.

Studies of Benzothiadiazine Derivatives As Hepatitis C Virus NS5B Polymerase Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics.